-
Something wrong with this record ?
The role of visfatin (PBEF/Nampt) in pregnancy complications
T. Pavlová, J. Novák, J. Bienertová-Vašků,
Language English Country Ireland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Biomarkers blood MeSH
- Cytokines blood immunology MeSH
- Diabetes, Gestational blood immunology MeSH
- Humans MeSH
- Nicotinamide Phosphoribosyltransferase blood immunology MeSH
- Obstetric Labor, Premature blood immunology MeSH
- Pre-Eclampsia blood immunology MeSH
- Pregnancy MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Visfatin (PBEF/Nampt) is an adipocytokine that exerts pleiotropic effects within the human body, particularly affecting its metabolism and immunity. Visfatin was originally identified as being secreted by peripheral blood lymphocytes acting as a pre-B-cell colony-enhancing factor (PBEF). However, it was subsequently reported to be expressed in almost every tissue of the human body, with visceral fat deposits being the main source of visfatin. In addition to its secreted form, visfatin may also be found intracellularly where it functions as a nicotinamide phosphoribosyltransferase (Nampt). Visfatin maternal plasma concentrations increase during pregnancy, suggesting its important role in this complicated process. Alterations in visfatin level also take place in patients during pregnancy complications. This review focuses on the ones that most commonly occur in connection with visfatin: preterm labor, pre-eclampsia and gestational diabetes mellitus. The review aims to provide a better understanding of the role of visfatin during pregnancy and the causes of its alteration in maternal plasma, highlighting the potential use of visfatin as a diagnostic marker of pregnancy complications in the future.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028118
- 003
- CZ-PrNML
- 005
- 20161025110048.0
- 007
- ta
- 008
- 161005s2015 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jri.2015.09.004 $2 doi
- 024 7_
- $a 10.1016/j.jri.2015.09.004 $2 doi
- 035 __
- $a (PubMed)26451650
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Pavlová, Tereza $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Building A18, Brno 62500, Czech Republic. Electronic address: tereza.pavlova1@gmail.com.
- 245 14
- $a The role of visfatin (PBEF/Nampt) in pregnancy complications / $c T. Pavlová, J. Novák, J. Bienertová-Vašků,
- 520 9_
- $a Visfatin (PBEF/Nampt) is an adipocytokine that exerts pleiotropic effects within the human body, particularly affecting its metabolism and immunity. Visfatin was originally identified as being secreted by peripheral blood lymphocytes acting as a pre-B-cell colony-enhancing factor (PBEF). However, it was subsequently reported to be expressed in almost every tissue of the human body, with visceral fat deposits being the main source of visfatin. In addition to its secreted form, visfatin may also be found intracellularly where it functions as a nicotinamide phosphoribosyltransferase (Nampt). Visfatin maternal plasma concentrations increase during pregnancy, suggesting its important role in this complicated process. Alterations in visfatin level also take place in patients during pregnancy complications. This review focuses on the ones that most commonly occur in connection with visfatin: preterm labor, pre-eclampsia and gestational diabetes mellitus. The review aims to provide a better understanding of the role of visfatin during pregnancy and the causes of its alteration in maternal plasma, highlighting the potential use of visfatin as a diagnostic marker of pregnancy complications in the future.
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a cytokiny $x krev $x imunologie $7 D016207
- 650 _2
- $a gestační diabetes $x krev $x imunologie $7 D016640
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nikotinamidfosforibosyltransferasa $x krev $x imunologie $7 D054409
- 650 _2
- $a předčasná porodní činnost $x krev $x imunologie $7 D007752
- 650 _2
- $a preeklampsie $x krev $x imunologie $7 D011225
- 650 _2
- $a těhotenství $7 D011247
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Novák, Jan $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Building A18, Brno 62500, Czech Republic. Electronic address: jnmedved@seznam.cz.
- 700 1_
- $a Bienertová-Vašků, Julie $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Building A18, Brno 62500, Czech Republic; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, Brno 65653, Czech Republic. Electronic address: Vasku.Julie@seznam.cz.
- 773 0_
- $w MED00002931 $t Journal of reproductive immunology $x 1872-7603 $g Roč. 112, č. - (2015), s. 102-10
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26451650 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161025110501 $b ABA008
- 999 __
- $a ok $b bmc $g 1166432 $s 952748
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 112 $c - $d 102-10 $e 20150921 $i 1872-7603 $m Journal of reproductive immunology $n J Reprod Immunol $x MED00002931
- LZP __
- $a Pubmed-20161005